0001209191-23-043439.txt : 20230726 0001209191-23-043439.hdr.sgml : 20230726 20230726170418 ACCESSION NUMBER: 0001209191-23-043439 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230724 FILED AS OF DATE: 20230726 DATE AS OF CHANGE: 20230726 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kauffman Michael CENTRAL INDEX KEY: 0001364719 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38542 FILM NUMBER: 231114325 MAIL ADDRESS: STREET 1: C/O KARYOPHARM THERAPEUTICS INC. STREET 2: 85 WELLS AVENUE, SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kezar Life Sciences, Inc. CENTRAL INDEX KEY: 0001645666 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473366145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-822-5600 MAIL ADDRESS: STREET 1: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-07-24 0 0001645666 Kezar Life Sciences, Inc. KZR 0001364719 Kauffman Michael C/O KEZAR LIFE SCIENCES, INC. 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 0 Stock Option (Right to Buy) 7.63 2023-07-24 4 D 0 8896 D 2029-06-24 Common Stock 8896 0 D Stock Option (Right to Buy) 2.28 2023-07-24 4 A 0 8896 A 2029-06-24 Common Stock 8896 8896 D Stock Option (Right to Buy) 5.60 2023-07-24 4 D 0 8896 D 2030-06-23 Common Stock 8896 0 D Stock Option (Right to Buy) 2.28 2023-07-24 4 A 0 8896 A 2030-06-23 Common Stock 8896 8896 D Stock Option (Right to Buy) 5.59 2023-07-24 4 D 0 26000 D 2031-06-27 Common Stock 26000 0 D Stock Option (Right to Buy) 2.28 2023-07-24 4 A 0 26000 A 2031-06-27 Common Stock 26000 26000 D Stock Option (Right to Buy) 4.80 2023-07-24 4 D 0 26000 D 2032-06-15 Common Stock 26000 0 D Stock Option (Right to Buy) 2.28 2023-07-24 4 A 0 26000 A 2032-06-15 Common Stock 26000 26000 D Fully vested and exercisable. On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. /s/ Marc Belsky, Attorney-in-Fact 2023-07-26